Jakobovits Aya
Known title: DirectorCIK: 0001823901
Associated companies
Transaction History
| ACET | ▲ Buy | Grant | 5,900 | $0 | 6/5/2024 | View on chart |
| ACET | ▲ Buy | Grant | 5,900 | $0 | 6/1/2023 | View on chart |
| ACET | ▼ Sell | Open Market | 2,000 | $28K | 3/9/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 2,000 | $28K | 3/9/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 2,000 | $30K | 2/16/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 2,000 | $30K | 2/16/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 4,000 | $56K | 2/9/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 4,000 | $56K | 2/9/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 2,000 | $34K | 1/5/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 2,000 | $34K | 1/5/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 6,000 | $108K | 1/3/2022 | View on chart |
| ACET | ▼ Sell | Open Market | 6,000 | $108K | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target
Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.
Adicet Bio shares positive Phase 1 lupus data, Wedbush lifts target. Adicet Bio announced that its Phase 1 study of Prula‑cel in lupus patients showed positive safety and efficacy signals, and the company is moving forward with plans for a pivotal trial. Wedbush analysts kept an Outperform rating and raised their price target to $28, reflecting confidence in the data. The news comes as the stock trades near its 52‑week high, with analyst consensus targets averaging $34.83.